Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    170
    ...
ATC Name B/G Ingredients Dosage Form Price
B01AC27 UPTRAVI B Selexipag - 800mcg 800mcg Tablet, film coated 275,097,581 L.L
L02BB03 PROSMIDE G Bicalutamide - 50mg 50mg Tablet, film coated 3,597,914 L.L
N03AX14 KEPCITAM G Levetiracetam - 500mg 500mg Tablet, film coated 2,933,608 L.L
A10BD13 VIPDOMET B Metformin HCl - 500mg, Alogliptin benzoate - 12.5mg Tablet, film coated 3,112,339 L.L
B01AC27 UPTRAVI B Selexipag - 1000mcg 1000mcg Tablet, film coated 275,097,581 L.L
J05AX12 TIVICAY B Dolutegravir - 50mg 50mg Tablet, film coated 54,508,037 L.L
L02BB03 CASODEX B Bicalutamide - 150mg 150mg Tablet, film coated 10,863,782 L.L
V06DD KETOSTERIL B Calcium - 0.05g, Total nitrogen - 36mg, L-Tyrosine - 30mg, L-Histidine - 38mg, L-Tryptophan - 23mg, L-Threonine - 53mg, L-Lysine Monoacetate - 105mg, Alpha Hydroxyanalogue-DL-Methionine, Calcium Salt - 59mg, Alpha Ketoanalogue-Valine,Calcium Salt - 86mg, Alpha Ketoanalogue-Phenylalanine,Calcium Salt - 68mg, Alpha-Ketoanalogue- Leucine,Calcium Salt - 101mg, Alpha-Ketoanalogue-DL-isoleucine,Calcium Salt - 67mg Tablet, film coated 3,950,897 L.L
A10BD13 VIPDOMET B Metformin HCl - 1,000mg, Alogliptin benzoate - 12.5mg Tablet, film coated 3,304,509 L.L
B01AC27 UPTRAVI B Selexipag - 1200mcg 1200mcg Tablet, film coated 275,097,581 L.L
J05AX18 PREVYMIS B Letermovir - 240mg 240mg Tablet, film coated 460,943,945 L.L
L01EA02 DALEUBIN G Dasatinib - 50mg 50mg Tablet, film coated 97,680,409 L.L
B01AC27 UPTRAVI B Selexipag - 1400mcg 1400mcg Tablet, film coated 275,097,581 L.L
J05AX18 PREVYMIS B Letermovir - 480mg 480mg Tablet, film coated 961,233,292 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 50mg 50mg Tablet, film coated 127,364,905 L.L
A10BD15 DIAFLOZIN PLUS G Metformin HCl XR - 1000mg, Dapagliflozin - 5mg Tablet, film coated 1,241,710 L.L
B01AC27 UPTRAVI B Selexipag - 1600mcg 1600mcg Tablet, film coated 275,097,581 L.L
L01EA02 ELPIDA G Dasatinib - 50mg 50mg Tablet, film coated 127,364,905 L.L
L02BB05 ERLEADA B Apalutamide - 60mg 60mg Tablet, film coated 254,089,146 L.L
N03AX14 LEVIPHAR G Levetiracetam - 500mg 500mg Tablet, film coated 1,451,350 L.L
L02BB05 ERLEADA B Apalutamide - 60mg 60mg Tablet, film coated 254,089,146 L.L
M01AB16 AIRTAL 100MG 20 B Aceclofenac - 100mg 100mg Tablet, film coated 471,689 L.L
N03AX14 LEVIPRAM 500 G Levetiracetam - 500mg 500mg Tablet, film coated 1,663,805 L.L
A10BD15 ZYGLOMET XR 5/1000 G Dapagliflozin - 5mg, Metformin HCl XR - 1000mg Tablet, film coated 2,578,386 L.L
G04BD02 URISPAS B Flavoxate HCl - 200mg 200mg Tablet, film coated 1,094,272 L.L
J01CA04 OSPAMOX G Amoxicillin (trihydrate) - 1g 1,000mg Tablet, film coated 657,246 L.L
L01EA02 DALEUBIN G Dasatinib - 20mg 20mg Tablet, film coated 79,249,265 L.L
L02BB06 NUBEQA B Darolutamide - 300mg Tablet, film coated 452,633,527 L.L
N03AX14 ZITERA G Levetiracetam - 500mg 500mg Tablet, film coated 2,203,902 L.L
N05CF04 INDUCTAL G Eszopiclone - 2mg 2mg Tablet, film coated 1,411,035 L.L
    ...
    170
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025